To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

NCT00222677

Conditions

1. Venous Thromboembolism
2. Deep Venous Thrombosis
3. Pulmonary Embolism
4. Atherosclerosis

Interventions

1. Drug: aspirin

MeSH:Pulmonary Embolism Thrombosis Atherosclerosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis

HPO:Atherosclerosis Deep venous thrombosis Pulmonary embolism Thromboembolism Type IV atherosclerotic lesion Venous thrombosis

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A ---

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A --- --- G21210A ---

Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as consolidation after, melphalan-based double autologous stem cell transplantation for previously untreated patients aged ≤65 years with symptomatic MM. Primary study endpoint is the rate of complete response (CR) plus near-complete response (nCR) to induction treatment. Secondary endpoints include the rate of CR plus nCR to double transplantation and subsequent consolidation therapy, time to progression (TTP), progression-free survival (PFS),overall survival (OS) and toxicity profile of both VTD and TD.

NCT01134484

Conditions

1. Multiple Myeloma

Interventions

1. Drug: Velcade
2. Drug: Thalidomide
3. Drug: Dexamethasone
4. Procedure: Peripheral Blood Stem Cell (PBSC) collection
5. Procedure: First Autologous Transplantation
6. Procedure: Second Autologous Transplantation

MeSH:Multiple Myeloma Neoplasms, Plasma Cell

HPO:Multiple myeloma

- Patient has a previous diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency. --- G21210A ---

The treatment of light-chain (AL) amyloidosis is directed against the plasma cells that produce the light-chain forming the amyloid deposits. The plasma cells can be killed and their growth can be stopped by drugs used in chemotherapy, such as cyclophosphamide, steroids, such as dexamethasone, and drugs that stimulate the immune system, such as lenalidomide. The present trial studies the efficacy and safety of the combination of cyclophosphamide, lenalidomide and dexamethasone in patients with AL amyloidosis who were previously treated and need further therapy.

NCT00607581

Conditions

1. Amyloidosis

Interventions

1. Drug: cyclophosphamide
2. Drug: lenalidomide
3. Drug: dexamethasone

MeSH:Immunoglobulin Light-chain Amyloidosis Amyloidosis

HPO:Amyloidosis

Prior diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency. --- G21210A ---